AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34526307
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (n=60) - maintain EPA+DHA at <150 mg/day and linoleic acid at around 7% of energy
Trial: 34153451
Drug: Oblong tablet
RxNorm normalized name: Cydonia oblonga leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oblong tablet (2.5 × 6 mm)
Trial: 34153451
Drug: Syrup (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup (3 ml glucose syrup)
Trial: 34153451
Drug: Mini-tablets (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-tablets (2 × 2 mm)
Trial: 34389407
Drug: CMT (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMT (combined modality therapy) with 20 Gy IF-RT after chemotherapy
Trial: 34389407
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (without IF-RT)
Trial: 34389407
Drug: CMT (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMT (combined modality therapy)
Trial: 32551097
Drug: Nefopam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (20 mg doses every 8 hours)
Trial: 32065485
Drug: Chlorhexidine patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine patches (CHG patches)
Trial: 34100788
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal daily workout without MHJB protocol)
Trial: 36316682
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual with information to improve lifestyle habits on their own
Trial: 34740351
Drug: Maternal counselling
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal counselling intervention (five monthly counselling sessions plus usual care)
Trial: 32493372
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (IM) + Patient-Controlled Epidural Anesthesia (PCEA)
Trial: 32493372
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (IM)
Trial: 32901255
Drug: Tolvaptan 15
RxNorm normalized name: tolvaptan 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 15 mg/day
Trial: 34895717
Drug: Optiflow THRIVE™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optiflow THRIVE™ at 70 L min‐1 oxygen
Trial: 34895717
Drug: Nasal prong
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal prong oxygen at 4 L min‐1
Trial: 35246228
Drug: EMDR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMDR therapy (ten biweekly 90-min sessions)
Trial: 33734299
Drug: Intermediate-dose prophylactic
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose prophylactic anticoagulation (enoxaparin, 1 mg/kg daily)
Trial: 33734299
Drug: Standard-dose prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose prophylactic anticoagulation (enoxaparin, 40 mg daily)
Trial: 33326064
Drug: Rosuvastatin/Ezetimibe (20/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin/Ezetimibe (20/10 mg)
Trial: 33820424
Drug: Supreme Drug-Eluting
RxNorm normalized name: Supreme
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supreme Drug-Eluting Stents (DES)
Trial: 34449295
Drug: 274 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 274 mg/day ADS-5102
Trial: 34449295
Drug: 137 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 137 mg/day ADS-5102
Trial: 32720916
Drug: Lottery scratchy
RxNorm normalized name: ALLERGENIC EXTRACTS DIAGNOSTIC SCRATCH TEST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lottery scratchy ticket reward for good bowel preparation
Trial: 35265981
Drug: Non-vitamin K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-vitamin K antagonist oral anticoagulant (NOAC)
Trial: 34837305
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine gluconate mouthwash (15 ml for 1 min)
Trial: 33755640
Drug: Ethyl chloride
RxNorm normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl chloride topical anesthetic spray
Trial: 36007724
Drug: CTgRT (Stereotactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTgRT (Stereotactic Body Radiation Therapy with CT guidance)
Trial: 36007724
Drug: MRgRT (Stereotactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRgRT (Stereotactic Body Radiation Therapy with MRI guidance)
Trial: 33526485
Drug: Rectal artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rectal artesunate (10 mg/kg) followed by intravenous artesunate (2.4 mg/kg)
Trial: 36876753
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (control)
Trial: 35317614
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg once daily for 7 days
Trial: 36942060
Drug: Melatonin 6
RxNorm normalized name: melatonin 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 6 mg daily for four weeks
Trial: 32640882
Drug: Serial 12-lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial 12-lead electrocardiograms once daily for five days
Trial: 33491027
Drug: Multicomponent exercise
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent exercise program (VIVIFRAIL) for 12 weeks, minimum 3 weekly sessions of 45–60 minutes
Trial: 33491027
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received physical daily training (yoga, cardio-dance or tai chi)
Trial: 32480417
Drug: Lowest VWF:Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest VWF:Ag quartile (0.43-0.92 IU/mL)
Trial: 35078765
Drug: SOC-F (fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC-F (fosfomycin at 100 mg/kg two times per day for up to 7 days)
Trial: 35078765
Drug: SOC (standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC (standard-of-care antibiotics)
Trial: 33482769
Drug: Denosumab 120
RxNorm normalized name: DENOSUMAB 120 MG/1.7 ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 120 mg subcutaneously once every 4 weeks, with loading doses on study days 8 and 15
Trial: 34148781
Drug: Cannabis preparations
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis preparations (most commonly cannabidiol)
Trial: 32243402
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine combined with western medicine
Trial: 32441241
Drug: Methionine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine plus cystine (Met+Cys) intake at 313 mg/day for P1 (2 to 6 weeks)
Trial: 32441241
Drug: Methionine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine plus cystine (Met+Cys) intake at 381 mg/day for P2 (8 to 12 weeks)
Trial: 32441241
Drug: Methionine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine plus cystine (Met+Cys) intake at 318 mg/day for P3 (14 to 18 weeks)
Trial: 32441241
Drug: Methionine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine plus cystine (Met+Cys) requirements for WG: 20 mg/g for P1, 22 mg/g for P2, 27 mg/g for P3
Trial: 32441241
Drug: Methionine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine plus cystine (Met+Cys) requirements for maintenance: 214 mg/kgBW0.75 for P1, 53 mg/kgBW0.75 for P2, 30 mg/kgBW0.75 for P3
Trial: 32867994
Drug: Dietary lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary lead nitrate at 3.20 mg/kg
Trial: 32867994
Drug: Dietary lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary lead nitrate at 33.20 mg/kg
Trial: 32867994
Drug: Dietary lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary lead nitrate at 63.20 mg/kg
Trial: 32867994
Drug: Dietary lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary lead nitrate at 93.20 mg/kg
Trial: 36008074
Drug: Neuromuscular electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular electrical stimulation (NMES) device, 8-week home-based intervention, footplate stimulation for 30 minutes daily and quadriceps stimulation for 20 minutes, five times a week.
Trial: 35708631
Drug: KGR-BG1 (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KGR-BG1 (1500 mg oral dose containing 1000 mg active component, twice daily for 6 weeks)
Trial: 35708631
Drug: Korean Red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean Red Ginseng Extract (1500 mg oral dose containing 1000 mg active component, twice daily for 6 weeks)
Trial: 35708631
Drug: Placebo (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1500 mg oral dose, twice daily for 6 weeks)
Trial: 32051147
Drug: Low-dose Sinemet
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Sinemet (levodopa plus carbidopa) for 2 weeks
Trial: 32051147
Drug: High-dose Sinemet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Sinemet (levodopa plus carbidopa) for 2 weeks
Trial: 32564076
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) 10 mg/kg daily for 12 months
Trial: 35176678
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) twice weekly
Trial: 35176678
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) once weekly
Trial: 35176678
Drug: Interpersonal Psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal Psychotherapy (IPT) twice weekly
Trial: 35176678
Drug: Interpersonal Psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal Psychotherapy (IPT) once weekly
Trial: 36448389
Drug: PVRU of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRU of 200 ml
Trial: 36448389
Drug: PVRU of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRU of 300 ml
Trial: 33727268
Drug: Local consolidation
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local consolidation radiation therapy (RT) and standard maintenance therapy
Trial: 32761610
Drug: Genetically predicted
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically predicted magnesium concentration (1 SD higher, SD: 0.08 mmol/L)
Trial: 32761610
Drug: Genetically predicted
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically predicted phosphorus concentration (1 SD higher, SD: 0.5 mg/dL)
Trial: 36228641
Drug: Colchicine 1·2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1·2 mg followed by 0·6 mg 2 h later and then 0·6 mg twice daily for 28 days
Trial: 36228641
Drug: Rivaroxaban 2·5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2·5 mg twice daily plus aspirin 100 mg once daily for 28 days
Trial: 36228641
Drug: Control (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (usual care) for rivaroxaban and aspirin
Trial: 34118178
Drug: Mobocertinib (TAK-788)
RxNorm normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mobocertinib (TAK-788) 20-160 mg
Trial: 34118178
Drug: Mobocertinib (120/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobocertinib (120/160 mg) under fasted or low-fat meal conditions
Trial: 34118178
Drug: Mobocertinib 160
RxNorm normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mobocertinib 160 mg in 1 of 2 capsule products
Trial: 32151367
Drug: Naldemedine 0.2
RxNorm normalized name: naldemedine 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naldemedine 0.2 mg once daily for 2 weeks (COMPOSE-4)
Trial: 32151367
Drug: Naldemedine 0.2
RxNorm normalized name: naldemedine 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naldemedine 0.2 mg once daily for 12 weeks (COMPOSE-5)
Trial: 34508607
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (300,000 IU cholecalciferol followed by 1400 IU cholecalciferol + 500 mg of calcium daily for 150 days)
Trial: 35421407
Drug: Dentapen (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentapen (1.8 mL/162 sec, ramp-up setting)
Trial: 35421407
Drug: Traditional syringe
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional syringe (1.8 mL/60 sec)
Trial: 32847902
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual from EIP services (TAU)
Trial: 32402523
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (control)
Trial: 36413125
Drug: Diazepam nasal
RxNorm normalized name: diazepam Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam nasal spray after an overnight fast
Trial: 36413125
Drug: Diazepam nasal
RxNorm normalized name: diazepam Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam nasal spray after a standardized high-fat, high-calorie breakfast
Trial: 34125734
Drug: Average treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average treatment effect (ATE) with no assumptions
Trial: 34125734
Drug: Average treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average treatment effect (ATE) with minimum assumptions
Trial: 34125734
Drug: Complier average
RxNorm normalized name: Complera
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Complier average treatment effect (complier ATE)
Trial: 33387498
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative body radiotherapy (SABR) with prescribed doses ranging from 24–60 Gy administered in three to eight fractions.
Trial: 33539760
Drug: HIV clinic-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV clinic-based buprenorphine plus naloxone treatment
Trial: 35050355
Drug: Urolithin A
RxNorm normalized name: Urolithin A
DrugBank: Urolithin A (DB15464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urolithin A (1000 mg daily for 4 months)
Trial: 32928313
Drug: 0.2% Povidone-Iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% Povidone-Iodine gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Trial: 32928313
Drug: 1% Hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Hydrogen peroxide gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Trial: 32928313
Drug: Neem extract
RxNorm normalized name: neem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neem extract (Azardirachta indica) gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Trial: 32928313
Drug: 2% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% hypertonic saline gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Trial: 32928313
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Trial: 36167636
Drug: Granisetron (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (1 mg twice daily) plus sertraline (100 mg daily initially followed by 200 mg daily after week 4)
Trial: 36167636
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus sertraline (100 mg daily initially followed by 200 mg daily after week 4)
Trial: 33315105
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg nilotinib
Trial: 33315105
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg nilotinib
Trial: 35072420
Drug: Coverage of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coverage of all buccal cusps (T2)
Trial: 35664443
Drug: Meningococcal conjugate
RxNorm normalized name: meningococcal conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal conjugate vaccine
Trial: 35796800
Drug: Potassium oxalate
RxNorm normalized name: POTASSIUM OXALATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium oxalate (Oxa-Gel BF)
Trial: 35796800
Drug: Potassium oxalate
RxNorm normalized name: POTASSIUM OXALATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium oxalate (Oxa-Gel BF) associated with low-power laser irradiation (POLL)
Trial: 35166158
Drug: Psilocybin-assisted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin-assisted treatment with supportive psychotherapy
Trial: 35166158
Drug: Psilocybin-assisted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin-assisted treatment
Trial: 33770708
Drug: Extended interval
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended interval dosing (EID) regimen (MDI 6.1 weeks)
Trial: 33770708
Drug: Standard interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard interval dosing (SID) regimen (MDI 4.5 weeks)
Trial: 32722731
Drug: Weekly yoga
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly yoga
Trial: 33676296
Drug: Systemic lidocaine
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic lidocaine (1.5 mg kg−1 bolus, followed by 2 mg kg−1 h−1 infusion)
Trial: 32770840
Drug: MgSO4 infusion
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MgSO4 infusion (30 mg/kg loading dose followed by 10 mg/kg/hr continuous infusion)
Trial: 32770840
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline (same loading and maintenance infusion rates as MgSO4)
Trial: 32490976
Drug: Baerveldt glaucoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baerveldt glaucoma implant (250-mm2)
Trial: 32757658
Drug: tPA dosing
RxNorm normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tPA dosing regimens for ultrasound-facilitated, catheter-directed fibrinolysis (8 mg/2 hours, 8 mg/4 hours, 12 mg/6 hours, and 24 mg/6 hours)
Trial: 32757658
Drug: tPA dosing
RxNorm normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tPA dosing regimens for ultrasound-facilitated, catheter-directed fibrinolysis
Trial: 32144974
Drug: Intra-articular oxygen-ozone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular oxygen-ozone therapy (O2O3)
Trial: 35721497
Drug: Plasmalogen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmalogen (2 mg per day)
Trial: 32988373
Drug: Single IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of fosaprepitant 150 mg
Trial: 36806623
Drug: 0.9 mg
RxNorm normalized name: estradiol 0.9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg of 0.1% oestradiol gel per day
Trial: 34323575
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment group (including weight losers and maintainers)
Trial: 35433384
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of oral magnesium powder
Trial: 33463492
Drug: Fat-modified enteral
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-modified enteral nutrition (EN) suspension
Trial: 34872040
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% plus dexamethasone 8 mg
Trial: 34176932
Drug: Intravenous landiolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous landiolol (started at 3 μg/min/kg dose and continued to a total of 50 mg; n=23)
Trial: 34176932
Drug: Intravenous landiolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous landiolol (n=23)
Trial: 35514746
Drug: Povidone-iodine 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone-iodine 0.5% and glycyrrhizic acid 2.5 mg/ml